期刊文献+

EB病毒潜伏膜蛋白2重组腺病毒的构建及其免疫效果的研究 被引量:5

Effective Induction of Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes in Mice by Latent Membrane Protein 2 Recombined Adenovirus
下载PDF
导出
摘要 为了进一步研究以EB病毒潜伏膜蛋白2穴LMP2)为靶抗原制备EB病毒相关肿瘤的治疗性疫苗,利用AdEasy系统构建了EBV鄄LMP2的重组腺病毒。PCR鉴定结果证实病毒DNA中含有目的基因的特异性片段;RT鄄PCR证明了外源基因在真核细胞中得以转录;免疫酶和Westernblot的结果也显示LMP2蛋白在真核细胞得到表达。将扩增后的病毒感染Hela细胞测定病毒滴度为1.5×109pfu/ml。将重组病毒以灌胃、肌肉注射和滴鼻的方式感染小鼠,经免疫荧光检测其特异性抗体,LDH法检测特异性CTL的杀伤作用,结果发现三种给药途径均可诱发小鼠针对LMP2的特异性体液免疫和细胞免疫,而用Ad5作为对照组的小鼠则没有引起相应的免疫反应。该研究将有益于进一步探索抗肿瘤特异性主动免疫作用在阻止肿瘤的生长、扩散或复发中的作用。对诱导机体产生特异性抗瘤活性有重要意义。 In order to develop an EBV-LMP2vaccine,we constructed recombined adenovirus(rAd)bearing the full-length cDNA for LMP2driven by CMV.As time-consuming and tedious conventional procedure for construction of rAd,we chose AdEasy system to construct rAds.PCR and dot blot showed the LMP2gene integrated into the genome of rAds.LMP2specific mRNA was detected in infected293cells by RT-PCR.We obtained the LMP2recombinant adenovirus by Immunoenzyme method and Western blot assays.The titer of amplified rAds was1.5×10 9 Pfu/ml.Balb/c mice were immunized by the rAds with three routes.Preliminary results showed the rAds could elicit LMP2specific cellular and humoral immune responses.
出处 《中国肿瘤》 CAS 2003年第1期45-47,共3页 China Cancer
基金 国家"973" "863"资助项目(G1998051201 2001AA217091)
关键词 EB病毒 潜伏膜蛋白2 重组腺病毒 构建 免疫效果 肿瘤 Epstein-Barr virus latent membrane protein2 CTL recombinant adenovirus
  • 相关文献

参考文献1

二级参考文献1

共引文献17

同被引文献44

  • 1吴云,徐容,曹广文,潘卫,陈秋莉,沈毅君,卢海妹,蔡春晓,邓松华.腺病毒介导mIFN-β基因转染的小鼠黑色素瘤细胞体内致瘤性及抗肿瘤作用的实验研究[J].中国药理学通报,2004,20(6):677-680. 被引量:4
  • 2王湛,周玲,吴小兵,卢觅佳,宣尧仙,左建民,李峰,王琦,叶树清,曾毅.Ad-LMP2重组腺病毒疫苗在恒河猴体内免疫效果的研究[J].中华实验和临床病毒学杂志,2006,20(2):63-65. 被引量:6
  • 3He TC, Zhou SD, Costa LT, et al. A simplified system for generating recombinant adenoviruses. Pro Natl Acad Sei, USA, 1998, 95: 2509-2514.
  • 4Huang DP. Epidemiology and etiology. In: van-Hasselt CA, Gibb AG,eds. Nasopharyngeal carcinoma. Chinese University Press,Hong Kong,1991, p23.
  • 5Rooney CM, Smith CA. Use of gene-modifled virus-specific T lymphocytes to control Epstein-Barr virus related lympholiferation. The Lancet, 1995,345: 9-13.
  • 6Schmidt C, Burrows SR, Sculley riB, et al. Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implication for vaccine strategies. Proc Natl Acad Sci USA, 1991, 88: 9478-9482.
  • 7Butterfield LH, Jilani SM, Chakraborty NG, et. al. Generation of mela-noma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol, 1998, 161: 5607-5613.
  • 8Wan YJ, Bramson B, Carter F, etal. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther. 1997. 8: 1355-1363.
  • 9Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol, 2000, 18: 245-273.
  • 10Redchenko IV, Rickinson AB. Accessing Epstein-Barr vires specific T cell memory with peptide loaded dendritic cells. J Virol, 1999, 73: 334--342.

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部